Table of Contents
1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents
- 4.1 List of Figures
- 4.2 List of Tables
5 Introduction
- 5.1 The Scope of this Report
- 5.2 Definitions
- 5.3 Abbreviations
6 Consider the Therapeutic Target for the Highest Therapeutic Investment
- 6.1.1 Carboxy-lyase Activity Targets
- 6.1.2 Catalytic Activity Targets
- 6.1.3 Cell Adhesion Molecule Activity Targets
- 6.1.4 Chaperone Activity Targets
- 6.1.5 Cysteine-Type Peptidase Activity Targets
- 6.1.6 Cytokine Activity Targets
- 6.1.7 DNA Binding Targets
- 6.1.8 DNA Repair Protein Targets
- 6.1.9 DNA Topoisomerase Activity Targets
- 6.1.10 DNA-Directed DNA Polymerase Activity Targets
- 6.1.11 Glutathione Transferase Activity Targets
- 6.1.12 G-Protein Coupled Receptor Activity Targets
- 6.1.13 Growth Factor Activity Targets
- 6.1.14 Hormone Activity Targets
- 6.1.15 Hydrolase Activity Targets
- 6.1.16 Kinase Activity Targets
- 6.1.17 Kinase Regulator Activity Targets
- 6.1.18 Ligand-Dependent Nuclear Receptor Activity Targets
- 6.1.19 Ligase Activity Targets
- 6.1.20 Lipid Kinase Activity Targets
- 6.1.21 Lipid Phosphatase Activity Targets
- 6.1.22 MHC Class I Receptor Activity Targets
- 6.1.23 Molecular Function Unknown Targets
- 6.1.24 Motor Activity Targets
- 6.1.25 Oxidoreductase Activity Targets
- 6.1.26 Phosphorylase Activity Targets
- 6.1.27 Protein Binding Targets
- 6.1.28 Protein Serine/Threonine Kinase Activity Targets
- 6.1.29 Protein Tyrosine Phosphatase Activity Targets
- 6.1.30 Protein-Tyrosine Kinase Activity Targets
- 6.1.31 Receptor Activity Targets
- 6.1.32 Receptor Binding Targets
- 6.1.33 Receptor Signaling Complex Scaffold Activity Targets
- 6.1.34 RNA Binding Targets
- 6.1.35 Serine-Type Peptidase Activity Targets
- 6.1.36 Structural Constituent Of Cytoskeleton Targets
- 6.1.37 Superoxide Dismutase Activity Targets
- 6.1.38 T Cell Receptor Activity Targets
- 6.1.39 Transcription Factor Activity Targets
- 6.1.40 Transcription Regulator Activity Targets
- 6.1.41 Translation Regulator Activity Targets
- 6.1.42 Transmembrane Receptor Activity Targets
- 6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- 6.1.44 Transporter Activity Targets
- 6.1.45 Other Targets
- 6.2 The Cancer Genome Project and Lymphoma Targets
- 6.2.1 Lymphoma Targets Present in the Cancer Gene Census and in the
Catalogue of Somatic Mutations in Cancer
- 6.3 Structure-based Drug Design in Lymphoma is Stimulated by Available
Structure Biological Targets
- 6.4 Target-Target Interactions among Identified Lymphoma Targets
- 6.5 The Drug-Target Interactome
- 6.6 Protein Expression Levels of Identified Drug Targets of Lymphoma Drugs
- 6.7 Pathway Analysis of Lymphoma Drug Targets
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline?
- 7.1 Terminated Drug Target Profiles in Lymphoma
- 7.2 Pre-Registration to being Marketed: New and Unique Drug Target
Profiles in the Lymphoma Pipeline
- 7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in
the Lymphoma Pipeline
- 7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the
Lymphoma Pipeline
- 7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in
the Lymphoma Pipeline
- 7.6 Preclinical Development: New and Unique Drug Target Profiles in the
Lymphoma Pipeline
- 7.7 Development Profiles of All Lymphoma Drug Target Profiles
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline Type of Compound
- 8.1 Small Molecules
- 8.1.1 Background
- 8.1.2 Targets in Lymphoma
- 8.2 Peptide/Protein Drugs
- 8.2.1 Background
- 8.2.2 Targets in Lymphoma
- 8.3 Antibodies and Antibody-like Structures
- 8.3.1 Background
- 8.3.2 Targets in Lymphoma
- 8.4 Nucleic Acid Therapies
- 8.4.1 Background
- 8.4.2 Targets in Lymphoma
- 8.5 Gene Therapy
- 8.5.1 Background
- 8.5.2 Targets in Lymphoma
- 8.6 The Competition Through Close Mechanistic Approximation Among Drugs in
Lymphoma
- 8.7 Compound Strategies based on Sub-Cellular Localization of Lymphoma
Drug Targets
9 Selecting a Sub-Indication of Lymphoma for Drug Development
- 9.1 B-cell Lymphoma
- 9.1.1 Players and their Compared Pipeline
- 9.1.2 Where is the Real Competition?
- 9.1.3 How Successful are They in Their Targeting Strategy?
- 9.2 Hodgkin' s Lymphoma
- 9.2.1 Players and their Compared Pipeline
- 9.2.2 Where is the Real Competition?
- 9.2.3 How Successful are They in Their Targeting Strategy?
- 9.3 Lymphoma (general)
- 9.3.1 Players and their Compared Pipeline
- 9.3.2 Where is the Real Competition?
- 9.3.3 How Successful are They in Their Targeting Strategy?
- 9.4 Non-Hodgkin' s Lymphoma
- 9.4.1 Players and their Compared Pipeline
- 9.4.2 Where is the Real Competition?
- 9.4.3 How Successful are They in Their Targeting Strategy?
- 9.5 T-cell Lymphoma
- 9.5.1 Players and their Compared Pipeline
- 9.5.2 Where is the Real Competition?
- 9.5.3 How Successful are They in Their Targeting Strategy?
10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator
- 10.1 Abbott
- 10.2 Abiogen
- 10.3 AEgera
- 10.4 Aeterna Zentaris
- 10.5 Affimed Therapeutics
- 10.6 Aida Pharmaceuticals
- 10.7 Alfa Wassermann
- 10.8 Alfacell
- 10.9 Allos Therapeutics
- 10.10 Amgen
- 10.11 Anadys Pharmaceuticals
- 10.12 Antigenics
- 10.13 Archer Biosciences
- 10.14 Ariad
- 10.15 Ascenta Therapeutics
- 10.16 Astellas
- 10.17 AstraZeneca
- 10.18 Attenuon
- 10.19 AVEO
- 10.20 Benitec
- 10.21 BioCryst Pharmaceuticals
- 10.22 Biogen Idec
- 10.23 Biolex
- 10.24 Boehringer Ingelheim
- 10.25 Borean Pharma
- 10.26 Bristol-Myers Squibb
- 10.27 BTG
- 10.28 Calistoga Pharmaceuticals
- 10.29 Cell Therapeutics
- 10.30 Cephalon
- 10.31 Cyclacel
- 10.32 Cylene Pharmaceuticals
- 10.33 Cytokinetics
- 10.34 Daiichi Sankyo
- 10.35 Dainippon Sumitomo Pharma
- 10.36 Dara Biosciences
- 10.37 Dynavax Technologies
- 10.38 Eisai
- 10.39 Eli Lilly
- 10.40 Enzon
- 10.41 EpiCept
- 10.42 Exelixis
- 10.43 Favrille
- 10.44 Gemin X Pharmaceuticals
- 10.45 Genentech
- 10.46 Genmab
- 10.47 GenPat77
- 10.48 Genta
- 10.49 Genzyme
- 10.50 GlaxoSmithKline
- 10.51 Gloucester Pharmaceuticals
- 10.52 Hayashibara
- 10.53 Hoffmann-La Roche
- 10.54 Human Genome Sciences
- 10.55 Hy BioPharma
- 10.56 ImClone Systems
- 10.57 Immunomedics
- 10.58 Inex
- 10.59 Innate Pharma
- 10.60 InNexus Biotechnology
- 10.61 Intracel
- 10.62 Italfarmaco
- 10.63 Johnson & Johnson
- 10.64 Kissei
- 10.65 Kyowa Hakko Kirin
- 10.66 Ligand
- 10.67 Lorus Therapeutics
- 10.68 MacroGenics
- 10.69 Meda
- 10.70 Medarex
- 10.71 MedImmune
- 10.72 MethylGene
- 10.73 Micromet
- 10.74 Nektar Therapeutics
- 10.75 National Institute of Health (USA)
- 10.76 Novartis
- 10.77 Oncothyreon
- 10.78 Pfizer
- 10.79 Pharmacyclics
- 10.80 PharmaMar
- 10.81 ProNAi Therapeutics
- 10.82 Reata Pharmaceuticals
- 10.83 Rigel
- 10.84 Sanofi-Aventis
- 10.85 Santaris Pharma
- 10.86 SBIO
- 10.87 Seattle Genetics
- 10.88 Shire
- 10.89 SuperGen
- 10.90 Takeda
- 10.91 Telik
- 10.92 Titan Pharmaceuticals
- 10.93 TopoTarget
- 10.94 Transgene
- 10.95 Trubion
- 10.96 Vaccinex
- 10.97 Vertex Pharmaceuticals
- 10.98 VGX Pharmaceuticals
- 10.99 Vion Pharmaceuticals
- 10.100 VioQuest
- 10.101 Wyeth
- 10.102 Xencor
- 10.103 Yakult Honsha
- 10.104 Zenyaku Kogyo
- 10.105 ZymoGenetics
- 10.106 Non-industrial Source
11 Disclaimer
12 Drug Index
List of Figures
- Figure 1: Overall Breakdown of the Included Lymphoma Therapeutic Pipeline
by Sub-Indication and Stage of Development
- Figure 2: Visualization of Target-Target Interactions Among Lymphoma Drug
Targets
- Figure 3: The Drug-Protein Interactome of Lymphoma Drugs - Clusters I
- Figure 4: The Drug-Protein Interactome of Lymphoma Drugs - Clusters II
- Figure 5: Head-to-Head Targeting Interactome of Lymphoma Drugs
- Figure 6: Distribution of Compound Types among Lymphoma Drugs
- Figure 7: Primary Sub-cellular Localization of Drug Targets
- Figure 8: Breakdown of the B-cell Lymphoma Pipeline (I) - Displaying
Number of Drugs, Target Profiles and Investigators by Stage of Development
- Figure 9: Breakdown of the B-cell Lymphoma Pipeline (II) - Displaying the
Number of Drugs by Compound Strategy and Stage of Development
- Figure 10: Breakdown of the Hodgkin' s Lymphoma Pipeline (I) - Displaying
Number of Drugs, Target Profiles and Investigators by Stage of Development
- Figure 11: Breakdown of the Hodgkin' s Lymphoma Pipeline (II) - Displaying
the Number of Drugs by Compound Strategy and Stage of Development
- Figure 12: Breakdown of the Lymphoma (general) Pipeline (I) - Displaying
Number of Drugs, Target Profiles and Investigators by Stage of Development
- Figure 13: Breakdown of the Lymphoma (general) Pipeline (II) - Displaying
the Number of Drugs by Compound Strategy and Stage of Development
- Figure 14: Breakdown of the Non-Hodgkin' s Lymphoma Pipeline (I) -
Displaying Number of Drugs, Target Profiles and Investigators by Stage of
Development
- Figure 15: Breakdown of the Non-Hodgkin' s Lymphoma Pipeline (II) -
Displaying the Number of Drugs by Compound Strategy and Stage of Development
- Figure 16: Breakdown of the T-cell Lymphoma Pipeline (I) - Displaying
Number of Drugs, Target Profiles and Investigators by Stage of Development
- Figure 17: Breakdown of the T-cell Lymphoma Pipeline (II) - Displaying the
Number of Drugs by Compound Strategy and Stage of Development
List of Tables
- Table 1: Competitive Pressure Force Among Lymphoma Drugs
- Table 2: Overview of Drug Target Profile Themes
- Table 3: Drug Targets of Lymphoma Drugs Present in the Catalogue of
Somatic Mutations in Cancer and in the Cancer Gene Census
- Table 4: Identity of Lymphoma Drug Targets with Available Biological
Structures
- Table 5: Number of Target-Target Interactions among Lymphoma Drug Targets
- Table 6: Drug-Protein Interactome Clusters
- Table 7: Lymphoma Drug Targets with Available Protein Expression Profiles
- Table 8: Pathway Summary
- Table 9: Drug Targets without any Identified Assigned Pathways
- Table 10: Pathway Profile According to BioCarta of Lymphoma Drug Targets
- Table 11: Pathway Profile According to KEGG of Lymphoma Drug Targets
- Table 12: Pathway Profile According to NetPath of Lymphoma Drug Targets
- Table 13: Number of Drug Target Profiles by their Highest Developmental
Stage and Uniqueness
- Table 14: Top Competitive Lymphoma Target Profiles
- Table 15: Terminated Drug Target Profiles in Lymphoma
- Table 16 New and Unique Lymphoma Targets in Pre-Registration to Marketed
- Table 17: New and Unique Lymphoma Targets in Phase III Clinical Development
- Table 18: New and Unique Lymphoma Targets in Phase II Clinical Development
- Table 19: The Competition Through Close Mechanistic Approximation Between
Phase II Lymphoma Drugs
- Table 20 New and Unique Lymphoma Targets in Phase I Clinical Development
- Table 21: The Competition Through Close Mechanistic Approximation Between
Phase I Lymphoma Drugs
- Table 22: New and Unique Lymphoma Targets in Preclinical Development
- Table 23: The Progression, Maturity and Competitive Comparison of Lymphoma
Drug Target Profiles in Development
- Table 24: Overview of Compound Strategy Competition in Lymphoma
- Table 25:Overview of the Competitive Landscape of Small Molecular Drugs in
Lymhpoma
- Table 26: Head-to-head Target Competing Small Molecule Drugs for the
Treatment of Lymphoma
- Table 27: The Competition Through Close Mechanistic Approximation Between
Small Molecule Drugs in Lymphoma
- Table 28: The Progression, Maturity and Competitive Comparison of Small
Molecule Lymphoma Drug Target Profiles in Development
- Table 29: The Progression, Maturity and Competitive Comparison of Peptide
Based Lymphoma Drug Target Profiles in Development
- Table 30:Overview of the Competitive Landscape of Protein Based Drugs in
Lymhpoma
- Table 31: The Competition Through Close Mechanistic Approximation Between
Protein Based Drugs in Lymphoma
- Table 32: The Progression, Maturity and Competitive Comparison of Protein
Based Lymphoma Drug Target Profiles in Development
- Table 33:Overview of the Competitive Landscape of Antibody Drugs in
Lymhpoma
- Table 34: The Competition Through Close Mechanistic Approximation Between
Antibody Drugs in Lymphoma
- Table 35: The Progression, Maturity and Competitive Comparison of
AntibodyLymphoma Drug Target Profiles Development in
- Table 36:Overview of the Competitive Landscape of Nucleic Acid Therapy
Drugs in Lymhpoma
- Table 37: The Progression, Maturity and Competitive Comparison of Nucleic
Acid Lymphoma Drug Target Profiles in Development
- Table 38: Vectors in Gene Therapy
- Table 39: The Progression, Maturity and Competitive Comparison of Gene
Therapy Lymphoma Drug Target Profiles in Development
- Table 40: The Competition Through Close Mechanistic Approximation Among
Drugs in Lymphoma
- Table 41: Compound Strategies based on Sub-Cellular Localization of
Lymphoma Drug Targets
- Table 42: Competitive Summary of Lymhpoma Drugs by Sub-Indication
- Table 43: Players in the Field of B-cell Lymphoma Drug Development and
their Compared Pipeline
- Table 44: The Competition Through Close Mechanistic Approximation Between
B-cell Lymphoma Drugs
- Table 45: The Progression, Maturity and Competitive Comparison of Drug
Target Profiles in B-cell Lymphoma Drug Development
- Table 46: Players in the Field of Hodgkin' s Lymphoma Drug Development and
their Compared Pipeline
- Table 47: The Competition Through Close Mechanistic Approximation Between
Hodgkin' s Lymphoma Drugs
- Table 48: The Progression, Maturity and Competitive Comparison of Drug
Target Profiles in Hodgkin' s Lymphoma Drug Development
- Table 49: Players in the Field of Lymphoma (general) Drug Development and
their Compared Pipeline
- Table 50: The Competition Through Close Mechanistic Approximation Between
Lymphoma (general) Drugs
- Table 51: The Progression, Maturity and Competitive Comparison of Drug
Target Profiles in Lymphoma (general )Drug Development
- Table 52: A) Investigators with Multiple Non-Hodgkin' s Lymphoma Drugs in
Development B) Investigators with Ceased, Discontinued or Suspended Drugs
- Table 53: Players in the Field of Non-Hodgkin' s Lymphoma Drug Development
and their Compared Pipeline
- Table 54: The Competition Through Close Mechanistic Approximation Between
Non-Hodgkin' s Lymphoma Drugs
- Table 55: The Progression, Maturity and Competitive Comparison of Drug
Target Profiles in Non-Hodgkin' s Lymphoma Drug Development
- Table 56: Players in the Field of T-cell Lymphoma Drug Development and
their Compared Pipeline
- Table 57: The Competition Through Close Mechanistic Approximation Between
T-cell Lymphoma Drugs
- Table 58: The Progression, Maturity and Competitive Comparison of Drug
Target Profiles in T-cell Lymphoma Drug Development
- Table 59: Abbott' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 60: Abiogen' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 61: AEgera' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 62: Aeterna Zentaris' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 63: Affimed Therapeutics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 64: Aida Pharmaceuticals' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 65: Alfa Wassermann' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 66: Alfacell' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 67: Allos Therapeutics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 68: Amgen' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 69: Anadys Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 70: Antigenics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 71: Archer Biosciences' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 72: Ariad' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 73: Ascenta Therapeutics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 74: Astellas' Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 75: AstraZeneca' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 76: Attenuon' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 77: AVEO' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 78: Benitec' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 79: BioCryst Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 80: Biogen Idec' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 81: Biolex' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 82: Boehringer Ingelheim' s Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 83: Borean Pharma' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 84: Bristol-Myers Squibb' s Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 85: BTG' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 86: Calistoga Pharmaceuticals' Included Lymphoma Pipeline
Composition and Competitive Fall-Out
- Table 87: Cell Therapeutics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 88: Cephalon' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 89: Cyclacel' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 90: Cylene Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 91: Cytokinetics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 92: Daiichi Sankyo' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 93: Dainippon Sumitomo Pharma' s Included Lymphoma Pipeline
Composition and Competitive Fall-Out
- Table 94: Dara Biosciences' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 95: Dynavax Technologies' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 96: Eisai' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 97: Eli Lilly' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 98: Enzon' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 99: EpiCept' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 100: Exelixis' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 101: Favrille' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 102: Gemin X Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 103: Genentech' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 104: Genmab' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 105: GenPat77' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 106: Genta' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 107: Genzyme' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 108: GlaxoSmithKline' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 109: Gloucester Pharmaceuticals' Included Lymphoma Pipeline
Composition and Competitive Fall-Out
- Table 110: Hayashibara' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 111: Hoffmann-La Roche' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 112: Human Genome Sciences' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 113: Hy BioPharma' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 114: ImClone Systems' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 115: Immunomedics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 116: Inex' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 117: Innate Pharma' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 118: InNexus Biotechnology' s Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 119: Intracel' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 120: Italfarmaco' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 121: Johnson & Johnson' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 122: Kissei' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 123: Kyowa Hakko Kirin' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 124: Ligand' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 125: Lorus Therapeutics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 126: MacroGenics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 127: Meda' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 128: Medarex' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 129: MedImmune' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 130: MethylGene' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 131: Micromet' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 132: Nektar Therapeutics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 133: National Institute of Health (USA)' s Included Lymphoma Pipeline
Composition and Competitive Fall-Out
- Table 134: Novartis' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 135: Oncothyreon' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 136: Pfizer' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 137: Pharmacyclics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 138: PharmaMar' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 139: ProNAi Therapeutics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 140: Reata Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 141: Rigel' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 142: Sanofi-Aventis' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 143: Santaris Pharma' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 144: SBIO' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 145: Seattle Genetics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 146: Shire' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 147: SuperGen' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 148: Takeda' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 149: Telik' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 150: Titan Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 151: TopoTarget' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 152: Transgene' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 153: Trubion' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 154: Vaccinex' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 155: Vertex Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 156: VGX Pharmaceuticals' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 157: Vion Pharmaceuticals' Included Lymphoma Pipeline Composition
and Competitive Fall-Out
- Table 158: VioQuest' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 159: Wyeth' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 160: Xencor' s Included Lymphoma Pipeline Composition and Competitive
Fall-Out
- Table 161: Yakult Honsha' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 162: Zenyaku Kogyo' s Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 163: ZymoGenetics' Included Lymphoma Pipeline Composition and
Competitive Fall-Out
- Table 164: Non-industrial source' s Included Lymphoma Pipeline Composition
and Competitive Fall-Out
|
Related Report
|
View Cart
